Spots Global Cancer Trial Database for congenital malformation
Every month we try and update this database with for congenital malformation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness | NCT04150120 | Preterm Birth Pediatric Cance... Hirschsprung Di... Congenital Malf... Congenital Hear... Nutrition Disor... | e-health device... | 3 Days - 47 Months | Lund University | |
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. |